Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Intelligent cancer therapy with synthetic biology methods

Descripción del proyecto

Un enfoque innovador para luchar contra el cáncer mediante circuitos sintéticos

Pese a que la inmunoterapia se ha convertido en una parte importante del tratamiento de algunos tipos de cáncer durante las últimas décadas, la cirugía, la radioterapia o la quimioterapia, solas o combinadas, siguen siendo las intervenciones más habituales. El proyecto financiado con fondos europeos InCanTeSiMo busca luchar contra el cáncer mediante la administración local y la activación de circuitos sintéticos que derrotan al cáncer. Los circuitos sintéticos detectarán el estado de la célula sobre la que se administran y actuarán solamente si detectan un estado patológico. Esta innovadora terapia contra el cáncer puede adaptarse al caso particular de cada paciente durante la fase de diseño de los circuitos sintéticos.

Objetivo

With InCanTeSiMo I aim to realize local delivery and activation of cancer-defeating synthetic circuits. Despite the advent of immunotherapy as promising treatment against a number of cancers, surgery, radio- or chemotherapy, alone or in combination, remain the most common interventions. While surgery and radiotherapy are mainly targeted to the cancer itself, chemotherapy has a systemic mode of action, affecting both healthy as well as diseased cells. An innovative way to fight cancer would be the use of synthetic circuits sensing the status of the cell into which they are delivered and acting only in response to a detected diseased status. This type of cancer therapy lends itself well to personalization, as each patient’s specific profile could be considered when designing the synthetic circuits. Since naked plasmid DNA cannot be simply released in the blood, the synthetic circuits must be encapsulated into protective vehicles, which should shield them from the immune system and accumulate them at the site of cancer. Moreover, to limit side effects due to the potential accumulation of the delivery vehicles in other body parts, it would be advantageous to locally activate the synthetic circuits with an external trigger, such as light. This would additionally allow activating the therapy at specific time points. This project comprises three major engineering efforts: 1) the establishment of cost-effective production of delivery vehicles able to specifically invade cancer cells; 2) the realization of new synthetic circuits functioning at the protein level that discern between healthy and cancer cells based on the amount of a metabolite and trigger apoptosis, or convert a pro-drug into the active drug, in the latter ones only; 3) the development of a novel red light-inducible protein-protein interaction tool.

Régimen de financiación

ERC-COG - Consolidator Grant

Institución de acogida

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG
Aportación neta de la UEn
€ 2 000 000,00
Dirección
FAHNENBERGPLATZ
79098 Freiburg
Alemania

Ver en el mapa

Región
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 2 000 000,00

Beneficiarios (1)